BioSpace News Archive

Neuronetics, Inc. announced a healthcare policy update from Aetna increases access for patients to the Company’s NeuroStar® Advanced Therapy.

LiVeritas Biosciences, Inc . today announced beta testing of their LiLii ™ platform, a next-generation, fully integrated laboratory ecosystem that uses proprietary LiVeritas ® AI (artificial intelligence) to simplify workflows, reduce inefficiencies, and streamline productivity for drug developers at all phases of development.

Anbio, a leading provider of innovative diagnostic Solutions, proudly presents the Anbio LAMP Solution, an innovative point-of-care Solution designed for easy-to-use but elegantly sophisticated qualitative diagnostics.

Ambrx Biopharma Inc., Ambrx (or the “Company”) (NASDAQ: AMAM), today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to Ambrx’s proprietary anti-PSMA antibody-drug conjugate (ADC) investigational therapy, ARX517, for the treatment of patients with metastatic castration-resistant prostate cancer (mCRPC) upon progression on an androgen receptor pathway inhibitor.

Synaptogenix, Inc. today announced that it entered into an agreement with Cleveland Clinic to conduct a phase 1 trial of Bryostatin-1 in multiple sclerosis (MS).

Kintor Pharmaceutical Limited announced that the company has initiated the long-term safety trial (the “Long-term Safety Trial”) of KX-826, a potential first-in-class androgen receptor (AR) antagonist for the treatment of androgenetic alopecia (AGA) developed in-house, in China and has completed the first patient enrollment today.

KayoThera, Inc. announces the strengthening of its financial resources through multiple grant awards and expansion of its previously announced Series A financing.

Agile Therapeutics, Inc.'s partnership with Afaxys Pharma is expected to play a key role in propelling the women’s healthcare company toward its $25-$30 million net annual revenue target for 2023.

SiPhox Health, the leader in building the next generation of lab-grade home health testing with silicon photonics, raised $27 million in funding including a $10M Seed financing and a $17M Series A round.

Roche (SIX: RO, ROG; OTCQX: RHHBY) will showcase a science-driven and patient-centric exhibit at the 2023 American Association of Clinical Chemistry (AACC) Scientific Meeting and Clinical Lab Expo, July 23-27 in Anaheim, California.